Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesA randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
Clinical Endocrinology, 09/15/09
Trainer PJ et al. – In patients suboptimally controlled on LAR, PM and P–LAR were equally well tolerated and effective in normalizing IGF–I, and overall clinical improvement was observed with both regimens. Thus, pegvisomant monotherapy and adjunctive therapy are equally viable options for the treatment of LAR–resistant acromegaly.
Related Articles
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 88%
The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 87%
Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09
Relevance Score: 87%
Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09
Relevance Score: 85%
ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly
Journal of Clinical Endocrinology and Metabolism, 10/14/09
Relevance Score: 85%
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Familial Cervical Paragangliomas with Lymph Node Metastasis Expressing Somatostatin Receptor Type 2A
Endocrine Pathology, 11/25/09
Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
International Journal of Obesity, 11/25/09
Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies
Oncology (Karger), 11/25/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
International Journal of Obesity, 11/25/09
Assessment of Regional Changes in Skeletal Metabolism Following 3 and 18 Months of Teriparatide Treatment
Journal of Bone and Mineral Research, 11/25/09
Sponsor
Article Search
Sponsor